Latest News

Kurma Partners close diagnostics fund at €50m

Liquid biopsy assay. © Worcester Polytechnic Institute (WPI)


by tg

The only investment fund dedicated to breakthrough diagnostics, Kurma Diagnostics 2, had its first closing at €50m.

Venture Capital company Kurma Partners SA (Paris/Munich) said the €50m committed to the Kurma Diagnostics Fund 2 (KDx2) will finance 15 companies specialised in the development of disruptive molecular diagnostic tools, smart and connected diagnostic devices or innovations based on Artificial Intelligence (AI). In 2015, Kurma Partner‘s first KDx fund closed at €35m.
   
KDx2 is backed by existing investors such as the European Investment Fund (EIF), the National Seed Fund 2, managed by Bpifrance, and BNP Paribaa, as well as by new investors such as French insurance Groupe VYV, France’s largest health and protection mutual insurance group, and Bedex & Associés, a private investor.
 

Novel COVID antibody enters clinical testing

In contrast to existing COVID-19 treatments, the safety design of COR-101 is optimised for the treatment of hospitalized COVID-19 patients with...

Next-gen COVID-19 vaccine good in preclinical tests

In contrast to injectable vaccines, the nasal jab seems capablet to induce mucosal immunity which is crucial to eliminate the virus instead only...

Janssen presents one-shot COVID-19 vaccine data

Janssen Pharmaceuticals’ Phase III adenoviral vector vaccine JNJ-78436735 gave immune protection over two and a half months after a single vaccine...

InteRNA Technologies secures €18.5m in Series B financing

Waterman Ventures and current shareholders Aglaia Oncology Funds and OostNL participated in the funding. The Utrecht-based...

Janssen to pledge COVID-19 vaccine to African Union

The announcement follows a contract signed last year with the global vaccine alliance Gavi to deliver up to 500 million doses of JNJ’ adenoviral...

EMA starts rolling review for Sputnik V vaccine

The EU applicant for Gam-COVID-Vac is R-Pharm Germany GmbH. The CHMP’s decision to start the rolling review is based on results from laboratory...

German researchers find reason for remdesivir's inefficiency

“We have come to a simple conclusion,” said Max Planck Director Patrick Cramer at the MPI for Biophysical Chemistry. “Remdesivir does interfere with...